These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21594976)

  • 1. Nonclinical support of pediatric drug development in a global context: an industry perspective.
    Cappon GD
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):269-72. PubMed ID: 21594976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
    Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of juvenile animal studies: a Japanese industry perspective.
    Shimomura K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):266-8. PubMed ID: 21594974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling.
    Tassinari MS; Benson K; Elayan I; Espandiari P; Davis-Bruno K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):261-5. PubMed ID: 21594977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of juvenile animal studies: a pediatric clinical perspective.
    Rose K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):252-3. PubMed ID: 21594978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of juvenile animal studies "What have we learned from preclinical juvenile toxicity studies? II".
    Bailey GP; Mariën D
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):273-91. PubMed ID: 22623019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of juvenile animal studies.
    Leconte I; Bailey G; Davis-Bruno K; Hew KW; Kim J; Silva Lima B; Liminga U; Moffit J; De Schaepdrijver L; Schmitt G; Tassinari M; Thompson K; Hurtt M
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):292-303. PubMed ID: 22623020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors.
    Silva-Lima B; Due Theilade-Thomsen M; Carleer J; Vidal JM; Tomasi P; Saint-Raymond A
    Birth Defects Res B Dev Reprod Toxicol; 2010 Dec; 89(6):467-73. PubMed ID: 20632393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile animal testing in drug development--is it useful?
    Baldrick P
    Regul Toxicol Pharmacol; 2010; 57(2-3):291-9. PubMed ID: 20350578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile toxicity: are we asking the right questions?
    Downes N
    Toxicol Pathol; 2012 Jul; 40(5):830-7. PubMed ID: 22407308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of juvenile toxicity.
    Barrow PC; Barbellion S; Stadler J
    Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing drugs for pediatric use: a role for juvenile animal studies?
    Baldrick P
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):381-9. PubMed ID: 15135215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.